On July 9, Elekta celebrated the 10th anniversary of the first clinical use of 3D Image Guided Radiation Therapy (IGRT) with the Elekta Synergy® system. The first commercial linear accelerator to bring 3D image guidance into the clinical workflow, Elekta Synergy combines soft issue imaging and treatment in a single system. Clinicians had at last attained the ability to visualize the treatment target, improving radiation therapy for cancer patients.
Crawley United Kingdom — Wednesday, July 17, 2013
Elekta Synergy Research Group defines IGRT history
Elekta Synergy and IGRT development began in 1997 with William Beaumont Hospital (Royal Oak, Mich., USA), with other world-class centers joining later to form the IGRT consortium. These included The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL, Amsterdam, The Netherlands), Princess Margaret Hospital (Toronto, Canada), The Christie Hospital (Manchester, UK), Thomas Jefferson University (Philadelphia, Pa., USA) and University Hospital of Würzburg (Würzburg, Germany). The collaboration with Elekta and this research group led to the creation of protocols driven by real-life clinical experience and a suite of software tools designed to support efficient workflow in today’s busy clinic.
“When we pursued CBCT in the mid-1990s, we were asking questions about the volumetric nature of patient treatment,” says John Wong, Ph.D., a research group member from William Beaumont Hospital and now Professor of Radiation Oncology and Molecular Radiation Sciences at The Johns Hopkins University School of Medicine. “Our effort was aided by the introduction of large area flat panel imaging technology and a willing partner in Elekta. It has been very rewarding to hear from different colleagues that CBCT has made a transformative impact in the practice of radiation therapy.”
David Jaffray, Ph.D., Head, Radiation Physics at Princess Margaret Hospital, adds: “Integration of image guidance onto the linear accelerator did more than improve treatment quality, it also opened our eyes to the dynamics of cancer therapy and has stimulated further innovation. It was an exciting time with physicists, clinicians and industry partners working together to change the way we treat cancer.”
The first use of the new IGRT technology occurred at NKI-AVL in July 2003, when three cancer patients were treated using IGRT on an Elekta Synergy system.
“CBCT image guidance has fundamentally changed the management of geometrical uncertainties in radiotherapy, enabling considerable margin reduction and thus improving the quality of radiation therapy,” states NKI-AVL’s Jan-Jakob Sonke, Ph.D.
Ten years after the first patient was treated at NKI-AVL, Elekta remains at the forefront of delivering clinically focused innovations in the field of IGRT. These innovations include advanced image guidance tools and 4D imaging with Intuity™ and Symmetry™ in XVI 4.5. On the immediate horizon is XVI 5.0, which will be enable clinicians to further refine imaging at the time of treatment.
“It is both humbling and gratifying that the impact of the technology developed by Elekta and our research partners as IGRT is now considered virtually commonplace in cancer clinics and hospitals worldwide,” says Bill Yaeger, Vice President Oncology, Elekta. “Elekta engineers and physicists in the UK should be very proud today of their efforts to develop a solution to a major clinical challenge. Today, the impact of this technology on the lives of cancer patients and their loved ones is immeasurable.”
XVI 5.0 is not available for sale or distribution in all markets. Please contact your local representative for more details.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.